ОПТИМАЛЬНАЯ САХАРОСНИЖАЮЩАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: СОВРЕМЕННЫЕ РЕКОМЕНДАЦИИ
Аннотация
в обзоре обсуждается проблема повышенного риска развития хронической сердечной недостаточности у пациентов с сахарным диабетом. В настоящее время сахарный диабет рассматривается как самостоятельный и независимый фактор развития сердечно-сосудистых катастроф. Приведены убедительные данные результатов крупнейших рандомизированных долгосрочных многоцентровых исследований: EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose), DEСLARE – TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events) по снижению риска развития сердечно-сосудистых событий у пациентов с сахарным диабетом на фоне оптимально подобранной эффективной сахароснижающей терапии. Обсуждается новый класс инновационных сахароснижающих препаратов с инсулиннезависимым механизмом действия – ингибиторов натрий-глюкозного котранспортера 2 типа. Подробно рассматриваются гликемические и негликемические фармакологические эффекты данной группы препаратов. Большое внимание привлекают кардиопротективные и нефропротективные свойства этих лекарственных средств. Обсуждаются последние рекомендации Американской диабетической ассоциации/ Европейской ассоциации по изучению диабета, Российской ассоциации эндокринологов («Алгоритмы специализированной медицинской помощи больным сахарным диабетом», 2019) по персонализации выбора сахароснижающих препаратов у пациентов с сахарным диабетом и хронической сердечной недостаточностью.
Литература
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск (дополненный). – М.; 2019. DOI: 10.14341/DM221S1.
2. Bailey C., Gross J., Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial // BMC Med. – 2013. – Vol. 11. – P. 43.
3. Baker W.L., Smyth L.R., Riche D.M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis // Am. Soc. Hypertens. – 2014. – Vol. 8, № 4. – Р. 269–275.
4. Bolinder J., Ljunggren O., Kullberg J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin // J. Clin. Endocrinol. Metab. – 2012. – Vol. 97. – Р. 1020–1031.
5. Davies M.Y., Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018 // Diabetes Care. - 2018. – Vol. 41. – P. 2669–701. DOI: 10.2337/dci18-003.
6. Ferrannini E., Mark M., Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis // Diabetes Care. – 2016. – Vol. 39(7). – P. 1108-1114. doi: 10.2337/dc16-0330
7. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition // Diabetes Care. – 2015. – Vol. 38, № 9. – Р. 1730–1735.
8. Filippatos T., Elisaf M. High density lipoprotein and cardiovascular diseases // World J. Cardiol. – 2013. – Vol. 5. – P. 210–214.
9. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus // Am J. Cardiol. - 2011. – Vol. 108(3 Suppl). – P.52B-8B.
10. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment // Nutr. Metab. Cardiovasc. Dis. – 2009. – Vol.19, № 5. – Р. 365–377.
11. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., Gheorghiade M., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B., Fonarow G.C. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). // Am Heart J. – 2007. – Vol. 154. – P. 277–278.
12. He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study // Arch Intern Med. - 2001. - № 161. - Р. 996-1002.
13. Hoeben E., De Winter W., Neyens M., Devineni D. et al. // Clin. Pharmacokinet. – 2016, Feb. – Vol. 55, № 2. – Р .209-223.
14. Kalra S., Singh V., Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review // Adv Ther. – 2016. – V. 33(9). – P. 1502-1518. doi: 10.1007/s12325-016-0379-5.
15. Кannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study // Am J. Cardiol. – 1974. – Vol. 34. – P. 29–3411
16. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study // JAMA. – 1979. – Vol. 241. – Vol. 2035–2038.
17. Lambers Heerspink H., Zeeuw De, Wie L. et al Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes // Diabetes Obes. Metab. – 2013. – Vol. 15. – P. 853–862.
18. Lombardi C., Spigoni V., Gorga E., Dei Cas A. Novel insight into the dangerous connection between diabetes and heart failure // Herz.- 2016 May. – Vol. 41(3). – Р. 201-7. doi: 10.1007/s00059-016-4415-7.
19. Lopaschuk G.D., Verma S. Empagliflozin’s fuel hypothesis: not so soon // Cell. Metab. – 2016. – Vol. 24, №2. – Р. 200–202.
20. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes // N. Engl. J. Med. – 2017, Jun 12; Epub.
21. Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Erondu N., Shaw W., Barrett T.D., Weidner-Wells M., Deng H., Matthews D.R., Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials // Lancet Diabetes Endocrinol. - 2018 Sep. – Vol. 6(9). – P. 691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
22. Rajeev S.P., Cuthbertson D.J., Wilding J.P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition // Diabetes Obes. Metab. – 2016. – Vol.18, №2. – Р.125–134.
23. Sahasrabudhe V., Terra S.G., Fountaine R.J. et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus / Poster presented at: EASD 2015 51st European Association for the Study of Diabetes; September 14, 2015; Stockholm, Sweden.
24. Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus // Cureus. – 2017, Oct 5. – Vol. 9. - № 10. – Р. 1751.
25. Scheen A.J., Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence // Diabetes Metab. – 2014. – Vol. 40(6 Suppl 1). – P. 4–11.
26. Seifalian A., Filippatos T., Joshi J., Mikhailidis D. Obesity and arterial compliance alterations // Curr. Vasc. Pharmacol.- 2010. – Vol. 8. – P. 155–168.
27. Sha S. D., Polidori T. et al. Effect of the sodium glucose co transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus // Diabetes Obes. Metab. – 2014. – Vol.16, № 11. – Р. 1087–1095.
28. Shah N., Deeb W., Choksi R., Epstein B. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus // Pharmacotherapy. – 2012. – Vol. 32. – P. 80–94.
29. Terami N., Ogawa D., Tachibana H., Hatanaka T. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice / PLoS One. - 2014 Jun 24. – Vol. 9(6)/ -e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.
30. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J. Med. - 2018 Nov 10. https://doi.org/10.1056/NEJMoa1812389. [Epub ahead of print].
31. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes// N Engl. J. Med. - 2015. – Vol. 373. – P. 2117–28.
2. Bailey C., Gross J., Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial // BMC Med. – 2013. – Vol. 11. – P. 43.
3. Baker W.L., Smyth L.R., Riche D.M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis // Am. Soc. Hypertens. – 2014. – Vol. 8, № 4. – Р. 269–275.
4. Bolinder J., Ljunggren O., Kullberg J. et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin // J. Clin. Endocrinol. Metab. – 2012. – Vol. 97. – Р. 1020–1031.
5. Davies M.Y., Alessio D.A., Fradkin J. et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018 // Diabetes Care. - 2018. – Vol. 41. – P. 2669–701. DOI: 10.2337/dci18-003.
6. Ferrannini E., Mark M., Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis // Diabetes Care. – 2016. – Vol. 39(7). – P. 1108-1114. doi: 10.2337/dc16-0330
7. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition // Diabetes Care. – 2015. – Vol. 38, № 9. – Р. 1730–1735.
8. Filippatos T., Elisaf M. High density lipoprotein and cardiovascular diseases // World J. Cardiol. – 2013. – Vol. 5. – P. 210–214.
9. Fonseca V.A. Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus // Am J. Cardiol. - 2011. – Vol. 108(3 Suppl). – P.52B-8B.
10. Giaccari A., Sorice G., Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment // Nutr. Metab. Cardiovasc. Dis. – 2009. – Vol.19, № 5. – Р. 365–377.
11. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., Gheorghiade M., O'Connor C.M., Sun J.L., Yancy C.W., Young J.B., Fonarow G.C. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). // Am Heart J. – 2007. – Vol. 154. – P. 277–278.
12. He J., Ogden L.G., Bazzano L.A. et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study // Arch Intern Med. - 2001. - № 161. - Р. 996-1002.
13. Hoeben E., De Winter W., Neyens M., Devineni D. et al. // Clin. Pharmacokinet. – 2016, Feb. – Vol. 55, № 2. – Р .209-223.
14. Kalra S., Singh V., Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review // Adv Ther. – 2016. – V. 33(9). – P. 1502-1518. doi: 10.1007/s12325-016-0379-5.
15. Кannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study // Am J. Cardiol. – 1974. – Vol. 34. – P. 29–3411
16. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study // JAMA. – 1979. – Vol. 241. – Vol. 2035–2038.
17. Lambers Heerspink H., Zeeuw De, Wie L. et al Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes // Diabetes Obes. Metab. – 2013. – Vol. 15. – P. 853–862.
18. Lombardi C., Spigoni V., Gorga E., Dei Cas A. Novel insight into the dangerous connection between diabetes and heart failure // Herz.- 2016 May. – Vol. 41(3). – Р. 201-7. doi: 10.1007/s00059-016-4415-7.
19. Lopaschuk G.D., Verma S. Empagliflozin’s fuel hypothesis: not so soon // Cell. Metab. – 2016. – Vol. 24, №2. – Р. 200–202.
20. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes // N. Engl. J. Med. – 2017, Jun 12; Epub.
21. Perkovic V., de Zeeuw D., Mahaffey K.W., Fulcher G., Erondu N., Shaw W., Barrett T.D., Weidner-Wells M., Deng H., Matthews D.R., Neal B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials // Lancet Diabetes Endocrinol. - 2018 Sep. – Vol. 6(9). – P. 691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
22. Rajeev S.P., Cuthbertson D.J., Wilding J.P. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition // Diabetes Obes. Metab. – 2016. – Vol.18, №2. – Р.125–134.
23. Sahasrabudhe V., Terra S.G., Fountaine R.J. et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus / Poster presented at: EASD 2015 51st European Association for the Study of Diabetes; September 14, 2015; Stockholm, Sweden.
24. Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus // Cureus. – 2017, Oct 5. – Vol. 9. - № 10. – Р. 1751.
25. Scheen A.J., Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence // Diabetes Metab. – 2014. – Vol. 40(6 Suppl 1). – P. 4–11.
26. Seifalian A., Filippatos T., Joshi J., Mikhailidis D. Obesity and arterial compliance alterations // Curr. Vasc. Pharmacol.- 2010. – Vol. 8. – P. 155–168.
27. Sha S. D., Polidori T. et al. Effect of the sodium glucose co transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus // Diabetes Obes. Metab. – 2014. – Vol.16, № 11. – Р. 1087–1095.
28. Shah N., Deeb W., Choksi R., Epstein B. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus // Pharmacotherapy. – 2012. – Vol. 32. – P. 80–94.
29. Terami N., Ogawa D., Tachibana H., Hatanaka T. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice / PLoS One. - 2014 Jun 24. – Vol. 9(6)/ -e100777. doi: 10.1371/journal.pone.0100777. eCollection 2014.
30. Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes // N Engl J. Med. - 2018 Nov 10. https://doi.org/10.1056/NEJMoa1812389. [Epub ahead of print].
31. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes// N Engl. J. Med. - 2015. – Vol. 373. – P. 2117–28.
Опубликована
2019-12-01
Как цитировать
ХАМНУЕВА, Лариса Юрьевна; ХАНТАКОВА, Екатерина Александровна; СЕРГЕЕВНА, Андреева Лариса.
ОПТИМАЛЬНАЯ САХАРОСНИЖАЮЩАЯ ТЕРАПИЯ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ И ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ: СОВРЕМЕННЫЕ РЕКОМЕНДАЦИИ.
Сибирский медицинский журнал (Иркутск) 16+, [S.l.], v. 159, n. 4, p. 5-9, дек. 2019.
ISSN 1815-7572. Доступно на: <http://smj.ismu.baikal.ru/index.php/osn/article/view/384>. Дата доступа: 23 дек. 2024
Выпуск
Раздел
Научные обзоры
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial» («Атрибуция — Некоммерческое использование») 4.0 Всемирная.
